NasdaqCM - Nasdaq Real Time Price USD

Sangamo Therapeutics, Inc. (SGMO)

Compare

0.7185

-0.0053

(-0.73%)

At close: April 11 at 4:00:01 PM EDT

0.7299

+0.01

+(1.59%)

After hours: April 11 at 7:54:27 PM EDT

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

RICHMOND, Calif., April 03, 2025--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM

Business Wire 8 days ago

SGMO
-0.73%
Q4 2024 Sangamo Therapeutics Inc Earnings Call

Q4 2024 Sangamo Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 24 days ago

SGMO
-0.73%
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

Sangamo Therapeutics Inc (SGMO) reports significant progress in its Fabry disease program and neurology therapies, while navigating financial hurdles and partnership negotiations.

GuruFocus.com 24 days ago

SGMO
-0.73%
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -22.22% and 52.51%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 25 days ago

SGMO
-0.73%
Sangamo: Q4 Earnings Snapshot

RICHMOND, Calif. AP) — Sangamo Therapeutics Inc. SGMO) on Monday reported a loss of $23.4 million in its fourth quarter.

Associated Press Finance 25 days ago

SGMO
-0.73%
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

RICHMOND, Calif., March 17, 2025--Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Business Wire 25 days ago

SGMO
-0.73%
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

RICHMOND, Calif., March 06, 2025--SANGAMO THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 EARNINGS CALL AND PARTICIPATION IN UPCOMING INVESTOR CONFERENCE

Business Wire last month

SGMO
-0.73%
Sangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89%

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...

Simply Wall St. last month

SGMO
-0.73%
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

RICHMOND, Calif., February 06, 2025--SANGAMO ANNOUNCES UPDATED PHASE 1/2 STAAR STUDY DATA IN FABRY SHOWING SUSTAINED BENEFIT, IMPROVEMENTS IN KIDNEY FUNCTION AND FAVORABLE SAFETY PROFILE

Business Wire 2 months ago

SGMO
-0.73%
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025

We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a look at where Sangamo Therapeutics Inc. (NASDAQ:SGMO) stands against the other small-cap stocks. Fifteen small-cap stocks—predominantly under the technology sector—are taking center stage this year, boasting triple- to quadruple-digit performance in their […]

Insider Monkey 3 months ago

SGMO
-0.73%
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More

PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

Zacks 3 months ago

PFE

SGMO
-0.73%
NVS
Top Midday Decliners

Sangamo Therapeutics (SGMO) shares plunged 55%, a day after the company said its partner, Pfizer (PF

PREMIUM
MT Newswires 3 months ago

SGMO
-0.73%
COCP
Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership

Sangamo Therapeutics' (SGMO) shares were sinking intraday Tuesday after the company said its partner

PREMIUM
MT Newswires 3 months ago

PFE

SGMO
-0.73%
Top Midday Stories: Sangamo Shares Fall After Pfizer Exits Collaboration; Dave Denies DOJ Allegations

The Dow Jones Industrial Average and the S&P 500 were basically flat, while the Nasdaq Composite was

PREMIUM
MT Newswires 3 months ago

PFE

SGMO
-0.73%
COMP
Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future

Sangamo faces steep drop after Pfizer ends partnership, raising concerns about its hemophilia therapy's future

GuruFocus.com 3 months ago

PFE

SGMO
-0.73%
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

Investopedia 3 months ago

SGMO
-0.73%
PFE
SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse

Investors continued to sell off shares in Sangamo Therapeutics Inc. (NASDAQ:SGMO) before market open on Tuesday following announcements that pharmaceutical giant Pfizer Inc. (NYSE:PFE) terminated their hemophilia A gene therapy co-development agreement. As of 8:53 am on Tuesday, shares of the company declined anew by 50.85 percent to $1.08 each. The previous day’s trading also […]

Insider Monkey 3 months ago

PFE

SGMO
-0.73%
Sangamo stock plummets 50% after Pfizer ends gene therapy deal

Sangamo Therapeutics Inc. (SGMO) shares plunged in Tuesday's pre-market trading by over 50% after Pfizer Inc. (PFE) terminated its partnership with the company. The two were collaborating on a gene therapy program to co-develop a treatment for hemophilia A. Sangamo is exploring "all options" to continue the program. Morning Brief co-hosts Madison Mills and Seana Smith break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Angel Smith

Yahoo Finance Video 3 months ago

SGMO
-0.73%
PFE
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:PFE). Pfizer decided to terminate the global collaboration and license agreement between the parties. Sangamo intends to explore all options to advance the program, including seeking a potential new colla

Benzinga 3 months ago

PFE

SGMO
-0.73%
Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership

Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

Pharmaceutical Technology 3 months ago

PFE

SGMO
-0.73%

Performance Overview

Return	SGMO	S&P 500 (^GSPC)
YTD	-29.56%	-8.81%
1-Year	+30.64%	+3.16%
3-Year	-86.69%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Q4 2024 Sangamo Therapeutics Inc Earnings Call

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates

Sangamo: Q4 Earnings Snapshot

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Sangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89%

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025

Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More

Top Midday Decliners

Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership

Top Midday Stories: Sangamo Shares Fall After Pfizer Exits Collaboration; Dave Denies DOJ Allegations

Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future

Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact

SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse

Sangamo stock plummets 50% after Pfizer ends gene therapy deal

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership

Performance Overview